NCT00480818已完成1 期
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2006年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Safety and tolerability
研究概览
简要总结
To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women of nonchildbearing potential aged 18 to 45 years
- •Elderly men or women aged 65 years and above as of study day
- •Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. Body weight for elderly subjects must be ≥45 kg.
排除标准
- •Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- •Any clinically important deviation from normal limits in physical examination, vital signs, digital 12-lead ECGs, or clinical laboratory test results.
- •Tobacco use or the consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before study day 1, or grapefruit or grapefruit-containing products 72 hours before study day 1, and until the end of the inpatient confinement period.
- •Elderly men or women aged 65 years and above as of study day
- •Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg. Body weight for elderly subjects must be ≥45 kg.
结局指标
主要结局
Safety and tolerability
次要结局
- Pharmacokinetics and pharmacodynamics
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531Alzheimer DiseaseNCT00479349Wyeth is now a wholly owned subsidiary of Pfizer32
终止
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315Alzheimer DiseaseNCT00474552Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese MalesAlzheimer DiseaseNCT00479297Wyeth is now a wholly owned subsidiary of Pfizer72
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy SubjectsAlzheimer DiseaseNCT00479700Wyeth is now a wholly owned subsidiary of Pfizer80
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy AdultsAlzheimer DiseaseNCT00479440Wyeth is now a wholly owned subsidiary of Pfizer56